RecruitingPhase 1NCT06143527
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for PCOS
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for the Treatment of Polycystic Ovary Syndrome
Sponsor
The Foundation for Orthopaedics and Regenerative Medicine
Enrollment
20 participants
Start Date
Nov 16, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
This trial will study the safety and efficacy of cultured allogeneic adult umbilical cord derived mesenchymal stem cells delivered intravenously for the treatment of Polycystic Ovary Syndrome.
Eligibility
Sex: FEMALEMin Age: 18 Years
Inclusion Criteria1
- • Ultrasound documented poly cystic ovary syndrome
Exclusion Criteria10
- Active infection
- Active cancer
- Chronic multisystem organ failure
- Pregnancy
- Clinically significant abnormalities on pre-treatment laboratory evaluation
- Medical condition that would (based on the opinion of the investigator) compromise patient's safety
- Continued drug abuse
- Previous organ transplant
- Hypersensitivity to sulfur
- Inability to supply proper informed consent
Interventions
BIOLOGICALAlloRx
Cultured allogeneic adult umbilical cord derived mesenchymal stem cells
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06143527
Related Trials
Glucose Profiles in Women With Polycystic Ovary Syndrome
NCT074837231 location
Adipokines in Polycystic Ovary Syndrome
NCT067930721 location
Study of the Effect of a Nutritional Supplement on Microbiota, Metabolic Control, Inflammatory Profile, and Quality of Life in Patients With Polycystic Ovary Syndrome.
NCT065512851 location
The Physiological Responses and Adaptation of Brown Adipose Tissue to Chronic Treatment With Beta3-Adrenergic Receptor Agonists
NCT030494621 location
Multidisciplinary Diagnosis and Treatment of Polycystic Ovary Syndrome
NCT060475741 location